BioXcel Therapeutics (BTAI) Stock Price, Quote, News & History | Benzinga

BioXcel Therapeutics Inc (BTAI) Stock Price, Quote, News & History

BTAINASDAQ

Trade with Public

Trade with Public

$0.8038

0.00530.66%

At close: Aug 21, 5:00 PM EST

$0.8089

0.00510.63%

After Hours: 7:46 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$0.81

Close

$0.80

Volume / Avg.

1.24M / 985.86K

Day Range

$0.79 - $0.86

52 Wk Range

0.74 - 5.60

Market Cap

$25.32M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

13.71%

Days to Cover

9.68

Recent BioXcel Therapeutics Inc News

Why Ross Stores Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Ross Stores beats estimates with Q2 financial results, shares jump 9.1%. Other gainers include RFAI, HOWL, SUGP, SDEV, ZKH, BTAI, SXTC, TREO, and ASST. Losers are JZ, DFNS, FLUX, and MMA.

Avi Kapoor

Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

Flexsteel Industries Inc (FLXS) reported better-than-expected Q4 results, with shares jumping 9% in pre-market trading. Other gainers include PFSA, EJH, XOS, WETO, SGLY, VOGX, WFF, AMLX, and ENRD. Losers include SNYR, XPON, NOMA, BTAI, and YOUL.

Avi Kapoor

This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See full changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.

Avi Kapoor

Why Are BioXcel Therapeutics Shares Down Friday?

BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.

Vandana Singh

BioXcel Therapeutics Stock Rallies Opioid Study Success

BioXcel Therapeutics' stock rises premarket after Phase 2 data show BXCL501 reduced opioid withdrawal symptoms and may rival Lucemyra.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-50.90M

Investing Cash Flow (TTM)

0

Financing Cash Flow (TTM)

46.13M

Free Cash Flow (TTM)

-50.90M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-4.77M

Analyst Trends and Forecast

2

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$116.77M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

24.32

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-321.82%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$3.69

Company Debt

Total Debt

$104.45M

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$8.41M

Total Cash

$12.84M

Debt to Equity

-

Issuance of Debt (TTM)

-$8.41M

Repayment of Debt (TTM)

-$8.41M

Key Statistics

Open

$0.81

Close

$0.80

Volume / Avg.

1.24M / 985.86K

Day Range

$0.79 - $0.86

52 Wk Range

0.74 - 5.60

Market Cap

$25.32M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

13.71%

Days to Cover

9.68

About

Sector

Health Care

Industry

Biotechnology

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeli...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy BioXcel Therapeutics (BTAI) stock?

A

You can purchase shares of BioXcel Therapeutics (NASDAQ:BTAI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioXcel Therapeutics (BTAI) competitors?

A

Other companies in BioXcel Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for BioXcel Therapeutics (BTAI) stock?

A

BioXcel Therapeutics has a consensus price target of $20.41.

Q

What is the current price for BioXcel Therapeutics (BTAI)?

A

The stock price for BioXcel Therapeutics (NASDAQ: BTAI) is $0.8089 last updated August 21, 2026 at 7:46 PM EDT.

Q

Does BioXcel Therapeutics (BTAI) pay a dividend?

A

There are no upcoming dividends for BioXcel Therapeutics.

Q

When is BioXcel Therapeutics (NASDAQ:BTAI) reporting earnings?

A

BioXcel Therapeutics does not have any upcoming earnings scheduled.

Q

Is BioXcel Therapeutics (BTAI) going to split?

A

There is no upcoming split for BioXcel Therapeutics.

Q

What sector and industry does BioXcel Therapeutics (BTAI) operate in?

A

BioXcel Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.